Cargando…

Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations

Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlot, Mariska C, Boekel, Laura, Kragt, Jolijn, Killestein, Joep, van Amerongen, Barbara M., de Jonge, Robert, den Heijer, Martin, Heijboer, Annemieke C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893545/
https://www.ncbi.nlm.nih.gov/pubmed/31731605
http://dx.doi.org/10.3390/nu11112774
_version_ 1783476222247829504
author Vlot, Mariska C
Boekel, Laura
Kragt, Jolijn
Killestein, Joep
van Amerongen, Barbara M.
de Jonge, Robert
den Heijer, Martin
Heijboer, Annemieke C.
author_facet Vlot, Mariska C
Boekel, Laura
Kragt, Jolijn
Killestein, Joep
van Amerongen, Barbara M.
de Jonge, Robert
den Heijer, Martin
Heijboer, Annemieke C.
author_sort Vlot, Mariska C
collection PubMed
description Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D), active vitD (1,25(OH)(2)D), inactive 24,25(OH)D, and VDBP were measured in 91 MS patients and 92 HCs. Bioavailable and free concentrations were calculated. No difference in FGF23 (p = 0.65) and 25(OH)D/24.25(OH)(2)D ratio (p = 0.21) between MS patients and HCs was observed. Bioavailable 25(OH)D and bioavailable 1.25(OH)(2)D were lower (p < 0.01), while VDBP concentrations were higher in MS patients (p = 0.02) compared with HCs, specifically in male MS patients (p = 0.01). In conclusion, FGF23 and 25(OH)D/24.25(OH)(2)D did not differ between MS patients and HCs, yet bioavailable VitD concentrations are of potential clinical relevance in MS patients. The possible immunomodulating role of VDBP and gender-related differences in the VD-FGF23 axis in MS need further study.
format Online
Article
Text
id pubmed-6893545
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68935452019-12-23 Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations Vlot, Mariska C Boekel, Laura Kragt, Jolijn Killestein, Joep van Amerongen, Barbara M. de Jonge, Robert den Heijer, Martin Heijboer, Annemieke C. Nutrients Article Vitamin D (VitD) insufficiency is common in multiple sclerosis (MS). VitD has possible anti-inflammatory effects on the immune system. The ratio between VitD metabolites in MS patients and the severity of the disease are suggested to be related. However, the exact effect of the bone-derived hormone fibroblast-growth-factor-23 (FGF23) and VitD binding protein (VDBP) on this ratio is not fully elucidated yet. Therefore, the aim is to study differences in total, free, and bioavailable VD metabolites and FGF23 between MS patients and healthy controls (HCs). FGF23, vitD (25(OH)D), active vitD (1,25(OH)(2)D), inactive 24,25(OH)D, and VDBP were measured in 91 MS patients and 92 HCs. Bioavailable and free concentrations were calculated. No difference in FGF23 (p = 0.65) and 25(OH)D/24.25(OH)(2)D ratio (p = 0.21) between MS patients and HCs was observed. Bioavailable 25(OH)D and bioavailable 1.25(OH)(2)D were lower (p < 0.01), while VDBP concentrations were higher in MS patients (p = 0.02) compared with HCs, specifically in male MS patients (p = 0.01). In conclusion, FGF23 and 25(OH)D/24.25(OH)(2)D did not differ between MS patients and HCs, yet bioavailable VitD concentrations are of potential clinical relevance in MS patients. The possible immunomodulating role of VDBP and gender-related differences in the VD-FGF23 axis in MS need further study. MDPI 2019-11-15 /pmc/articles/PMC6893545/ /pubmed/31731605 http://dx.doi.org/10.3390/nu11112774 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vlot, Mariska C
Boekel, Laura
Kragt, Jolijn
Killestein, Joep
van Amerongen, Barbara M.
de Jonge, Robert
den Heijer, Martin
Heijboer, Annemieke C.
Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
title Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
title_full Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
title_fullStr Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
title_full_unstemmed Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
title_short Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
title_sort multiple sclerosis patients show lower bioavailable 25(oh)d and 1,25(oh)(2)d, but no difference in ratio of 25(oh)d/24,25(oh)(2)d and fgf23 concentrations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893545/
https://www.ncbi.nlm.nih.gov/pubmed/31731605
http://dx.doi.org/10.3390/nu11112774
work_keys_str_mv AT vlotmariskac multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations
AT boekellaura multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations
AT kragtjolijn multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations
AT killesteinjoep multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations
AT vanamerongenbarbaram multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations
AT dejongerobert multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations
AT denheijermartin multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations
AT heijboerannemiekec multiplesclerosispatientsshowlowerbioavailable25ohdand125oh2dbutnodifferenceinratioof25ohd2425oh2dandfgf23concentrations